Company Filing History:
Years Active: 2002-2025
Title: The Innovative Journey of Ann W. Newman
Introduction
Ann W. Newman, an accomplished inventor based in Lafayette, Indiana, has made significant contributions to the field of medicinal chemistry. With a total of seven patents to her name, she has focused on the development of solid forms of critical pharmaceutical compounds aimed at treating various diseases and disorders. Her work reflects a commitment to innovation and the advancement of healthcare solutions.
Latest Patents
Among her latest patents is the development of solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid. This patent includes comprehensive details on compositions and methods for making these solid forms, as well as their applications in treating numerous medical conditions. The advanced solid forms signify an important step forward in the accessibility and effectiveness of therapeutic treatments.
Career Highlights
Throughout her career, Ann has collaborated with prestigious companies in the pharmaceutical industry, including Akebia Therapeutics, Inc. and Bristol-Myers Squibb Company. Her extensive work experience has allowed her to refine her expertise and contribute meaningfully to groundbreaking advances in medicine.
Collaborations
In addition to her corporate affiliations, Ann has worked alongside notable colleagues in her field, including James Densmore Copp and Anne Luong. These collaborations have played a pivotal role in enriching her research and enhancing the impact of her inventions.
Conclusion
Ann W. Newman exemplifies the spirit of innovation in the pharmaceutical industry through her unwavering dedication to improving healthcare. With her impressive portfolio of patents and impactful collaborations, she continues to pave the way for future advancements, contributing significantly to the science of medication and treatment methods. Her legacy as an inventor highlights the critical role of creativity and perseverance in the pursuit of medical excellence.